Platelet Rich Plasma (PRP) Market Size, Share, Growth, and Industry Analysis, By Type ( Pure Platelet Rich Plasma,Leukocyte Rich Platelet Rich Plasma,Others ), By Application ( Orthopedics,Cosmetic Surgery & Dermatology,Ophthalmic Surgery,Neurosurgery,General Surgery,Others ), Regional Insights and Forecast to 2035

Platelet Rich Plasma (PRP) Market Overview

The global Platelet Rich Plasma (PRP) size is projected to grow from USD 437 million in 2026 to USD 487.7 million in 2027, reaching USD 1174 million by 2035, expanding at a CAGR of 11.6% during the forecast period.

The Platelet Rich Plasma (PRP) Market is characterized by increasing procedural volumes across orthopedics, dermatology, and sports medicine, with more than 10 million PRP procedures estimated globally per year as of 2024. Platelet concentrations in PRP formulations typically range from 3x to 7x baseline platelet counts, compared to normal blood platelet levels of 150,000–350,000 platelets/µL. Over 60% of PRP utilization is concentrated in musculoskeletal indications, while cosmetic applications account for nearly 25% of procedures. More than 4,000 clinical studies have been published on PRP since 2000, with over 1,200 studies added between 2020 and 2024, reflecting expanding research and commercialization activities.

In the United States, the Platelet Rich Plasma (PRP) Market Size is driven by over 32 million musculoskeletal injuries reported annually and nearly 7.5 million orthopedic procedures conducted each year. Approximately 1.2 million PRP injections are performed annually in the U.S., with over 45% linked to sports medicine and orthopedic practices. The country accounts for nearly 38% of global PRP procedure volume. More than 8,000 clinics and outpatient surgical centers in the U.S. offer PRP-based therapies, and around 65% of sports medicine specialists report incorporating PRP in at least 1 treatment protocol.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 62% of PRP demand is linked to musculoskeletal disorders, 48% of sports injury patients opt for biologic therapies, and 55% of orthopedic surgeons report increased PRP usage, while 41% of outpatient centers prioritize regenerative procedures.
• Major Market Restraint: Approximately 37% of insurance providers exclude PRP coverage, 46% of patients cite high out-of-pocket costs, 33% of clinicians report inconsistent clinical outcomes, and 29% of regulatory bodies classify PRP under restricted biologic frameworks.
• Emerging Trends: Nearly 52% of aesthetic clinics integrate PRP with microneedling, 44% of dermatologists combine PRP with laser therapies, 39% growth in hair restoration procedures involves PRP, and 31% of new protocols use leukocyte-modified formulations.
• Regional Leadership: North America holds nearly 40% procedure share, Europe accounts for 28%, Asia-Pacific represents 22%, and Middle East & Africa collectively contribute around 10% of total global PRP applications.
• Competitive Landscape: The top 5 manufacturers control approximately 58% of device distribution, 47% of clinics prefer closed-system PRP kits, 35% of suppliers operate in over 20 countries, and 26% market share is concentrated among 2 major companies.
• Market Segmentation: Orthopedics contributes nearly 60% of application share, cosmetic surgery holds 25%, ophthalmic and neurosurgery together account for 8%, while pure PRP represents 54% of type-based utilization versus 38% leukocyte-rich PRP.
• Recent Development: Between 2023 and 2025, 18% increase in FDA-cleared PRP devices occurred, 22% rise in combination biologic trials was recorded, 30% of new launches featured automated centrifugation, and 27% of manufacturers expanded production capacity.

Latest Trends

The Platelet Rich Plasma (PRP) Market Trends indicate growing adoption of closed-system centrifugation kits, which account for nearly 57% of total device installations in 2024. Automated PRP preparation systems reduce preparation time by 35% compared to manual systems, improving clinical workflow efficiency in over 62% of outpatient facilities. In cosmetic dermatology, PRP combined with microneedling has shown up to 48% improvement in skin elasticity scores across 12-week treatment cycles.

Hair restoration clinics report that approximately 43% of non-surgical hair regrowth treatments now incorporate PRP injections. In orthopedics, nearly 68% of sports injury clinics in developed economies use PRP for tendonitis and ligament injuries. More than 1,500 ongoing clinical trials globally are evaluating PRP efficacy in rotator cuff injuries, osteoarthritis, and chronic wounds. Additionally, platelet activation protocols using calcium chloride or thrombin have increased by 29% in research settings, reflecting innovation in formulation standards and expanding Platelet Rich Plasma (PRP) Market Growth indicators.

Market Dynamics

DRIVER

Rising prevalence of musculoskeletal and sports-related injuries.

More than 1.71 billion people globally suffer from musculoskeletal conditions, while 528 million individuals are diagnosed with osteoarthritis. In the United States alone, approximately 32 million adults are affected by osteoarthritis, creating substantial demand for non-surgical regenerative therapies. Sports-related injuries account for nearly 3.5 million cases annually in North America, and approximately 30% of adolescent injuries are sports-associated. PRP therapy adoption is reported in nearly 55% of sports rehabilitation centers, with about 49% of treated knee osteoarthritis patients reporting pain reduction within 6 months. Orthopedic procedures exceed 7 million annually in developed economies, and nearly 52% of sports medicine clinics integrate PRP into tendon and ligament repair protocols. Platelet concentrations in PRP formulations reach up to 7x baseline levels, enhancing growth factor release by approximately 200%–300% compared to normal plasma. These factors significantly strengthen the Platelet Rich Plasma (PRP) Market Outlook and support sustained procedural expansion in regenerative orthopedics and injury management.

RESTRAINT

Lack of standardized preparation protocols.

Despite strong clinical interest, the Platelet Rich Plasma (PRP) Market Analysis identifies standardization gaps as a major restraint. Variability in platelet concentration across different PRP systems can reach up to 33% deviation, impacting reproducibility of clinical outcomes. Nearly 42% of published clinical studies highlight heterogeneity in preparation methods, including centrifugation speed, spin time, and leukocyte inclusion levels. Approximately 37% of private insurers in developed markets categorize PRP as experimental for certain orthopedic indications, limiting reimbursement coverage. Out-of-pocket payment requirements affect nearly 46% of patients, contributing to procedural hesitancy. In addition, regulatory classifications differ across more than 20 healthcare jurisdictions, with about 29% of regulatory bodies applying stricter biologic product frameworks. Around 25% of small clinics cite capital investment barriers in acquiring automated centrifugation systems. These combined factors restrict faster Platelet Rich Plasma (PRP) Market Share expansion and slow adoption in price-sensitive healthcare environments.

OPPORTUNITY

Expansion in cosmetic and dermatology applications.

The Platelet Rich Plasma (PRP) Market Opportunities landscape is strongly influenced by the growth of aesthetic medicine and minimally invasive procedures. Globally, more than 25 million cosmetic procedures are performed annually, with nearly 75% categorized as minimally invasive. PRP is incorporated into approximately 32% of non-surgical facial rejuvenation treatments, particularly in combination with microneedling and laser resurfacing therapies. Hair restoration procedures have increased significantly, with nearly 40% of non-surgical hair regrowth treatments utilizing PRP injections delivered in 3-session protocols. Clinical evaluations demonstrate up to 48% improvement in skin elasticity within 12 weeks of PRP-based therapy. In Asia-Pacific, aesthetic clinic openings increased by nearly 31% over the past two years, expanding PRP service availability. Additionally, about 44% of dermatology clinics in developed markets now offer PRP-based anti-aging and scar revision services. The integration of automated systems in nearly 58% of clinics enhances procedural efficiency and safety, creating scalable B2B opportunities for device manufacturers and service providers across emerging and mature healthcare markets.

CHALLENGE

High procedure costs and limited insurance coverage.

Cost sensitivity and clinical variability remain critical challenges in the Platelet Rich Plasma (PRP) Industry Analysis. PRP treatment cycles often require 1 to 3 injections per indication, and approximately 46% of patients undergo repeat sessions within 12 months, increasing cumulative expenditure. Nearly 29% of clinics report patient reluctance due to out-of-pocket costs in non-reimbursed settings. Furthermore, inconsistencies in leukocyte concentration can lead to inflammatory response variations of up to 22%, affecting clinical predictability. About 18% of randomized trials report mixed efficacy outcomes depending on formulation type and injection protocol. Standardized dosing guidelines are absent in nearly 60% of treatment frameworks, complicating physician decision-making. Additionally, more than 35% of emerging market healthcare facilities lack advanced centrifugation equipment required for optimized platelet yield consistency. These operational, financial, and clinical evidence limitations present measurable obstacles within the Platelet Rich Plasma (PRP) Market Forecast, particularly for broader hospital network integration and government-supported healthcare programs.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The Platelet Rich Plasma (PRP) Market Analysis categorizes the industry by type and application, with orthopedics contributing nearly 60% of total procedures and cosmetic surgery accounting for approximately 25%. By type, pure PRP represents 54% share, leukocyte-rich PRP accounts for 38%, and others comprise 8%. Over 70% of hospital-based procedures use closed-system kits, while 30% rely on manual centrifugation. Application-based segmentation highlights musculoskeletal dominance, followed by dermatology and specialized surgical segments contributing a combined 15%.

By Type

Pure Platelet Rich Plasma (P-PRP): Pure Platelet Rich Plasma (P-PRP) holds approximately 54% of the global Platelet Rich Plasma (PRP) Market Share, primarily due to its lower leukocyte concentration and reduced inflammatory response profile. Platelet concentrations in P-PRP systems typically range between 3x and 5x baseline platelet levels, compared to standard blood platelet counts of 150,000–350,000 platelets/µL. Nearly 63% of dermatology clinics prefer P-PRP for facial rejuvenation and acne scar revision treatments. In aesthetic medicine, about 45% of non-surgical facial procedures incorporate pure PRP protocols. Orthopedic specialists report that approximately 28% of cartilage regeneration studies utilize P-PRP formulations to minimize post-injection inflammation. Furthermore, automated closed-system devices used in over 57% of outpatient facilities are optimized for producing leukocyte-poor PRP, reinforcing the dominance of P-PRP in both cosmetic and joint-related applications within the Platelet Rich Plasma (PRP) Industry Analysis.

Leukocyte Rich Platelet Rich Plasma (L-PRP): Leukocyte-Rich Platelet Rich Plasma (L-PRP) represents nearly 38% of total Platelet Rich Plasma (PRP) Market Size, largely driven by orthopedic and sports injury applications. L-PRP formulations typically achieve platelet concentrations between 4x and 7x baseline levels, with leukocyte presence increasing inflammatory cytokine release by approximately 22%, which may enhance tissue repair in chronic tendon injuries. About 59% of sports medicine clinics prefer L-PRP for ligament and tendon healing protocols. In knee osteoarthritis studies, nearly 41% of clinical trials evaluate leukocyte-rich formulations for improved symptomatic relief within 6-month follow-up periods. Around 35% of PRP kit manufacturers now offer adjustable leukocyte concentration systems, allowing clinicians to tailor inflammatory responses based on treatment indication. The use of L-PRP in musculoskeletal injuries contributes to nearly 52% of orthopedic PRP applications, strengthening its role in the Platelet Rich Plasma (PRP) Market Outlook for regenerative therapies.

Others: Other PRP derivatives, including platelet-rich fibrin (PRF) and activated PRP matrices, account for approximately 8% of the global Platelet Rich Plasma (PRP) Market Share. PRF applications are expanding in dental and maxillofacial surgeries, where nearly 34% of advanced implant procedures incorporate platelet-based fibrin membranes to enhance osseointegration. Activated PRP systems utilizing calcium chloride or thrombin demonstrate growth factor release improvements of nearly 27% compared to non-activated systems. Around 19% of experimental wound healing trials are currently evaluating fibrin-based platelet matrices. In neurosurgical and ophthalmic research settings, approximately 14% of pilot studies assess PRP-derived membranes for tissue adhesion and regeneration. Although representing a smaller share, these specialized variants contribute to technological diversification and niche clinical applications within the Platelet Rich Plasma (PRP) Industry Report.

By Application

Orthopedics: Orthopedics dominates the Platelet Rich Plasma (PRP) Market Analysis with nearly 60% of total global procedure share. Globally, more than 1.71 billion people suffer from musculoskeletal disorders, and over 528 million individuals are diagnosed with osteoarthritis. In developed healthcare systems, approximately 7 million joint-related procedures annually involve regenerative adjunct therapies, including PRP. Around 52% of sports rehabilitation centers utilize PRP for tendonitis and ligament injuries. Clinical observations indicate that nearly 49% of knee osteoarthritis patients report measurable pain reduction within 6 months following PRP injection protocols. In sports medicine, PRP is integrated into roughly 55% of non-surgical injury management programs, reinforcing orthopedics as the primary revenue-generating and volume-leading segment in the Platelet Rich Plasma (PRP) Market Growth trajectory.

Cosmetic Surgery & Dermatology: Cosmetic Surgery & Dermatology account for approximately 25% of global Platelet Rich Plasma (PRP) Market Share, supported by rising demand for minimally invasive procedures. Worldwide, more than 25 million aesthetic procedures are performed annually, with nearly 75% classified as minimally invasive. PRP is incorporated in around 32% of facial rejuvenation treatments, particularly in combination with microneedling and laser therapies. Hair restoration clinics report that nearly 40% of non-surgical hair regrowth procedures utilize PRP injections administered in 3-session treatment cycles. Skin elasticity improvement studies demonstrate up to 48% enhancement within 12-week evaluation periods when PRP is combined with collagen induction therapy. Approximately 44% of dermatology clinics in developed markets offer PRP-based treatments, making this segment a rapidly expanding vertical within the Platelet Rich Plasma (PRP) Market Opportunities landscape.

Ophthalmic Surgery: Ophthalmic Surgery contributes nearly 4% of the total Platelet Rich Plasma (PRP) Market Size, primarily in dry eye management and corneal healing applications. PRP-derived eye drops have demonstrated symptom score improvements of approximately 38% over 12-week clinical studies in moderate dry eye patients. Around 18% of tertiary ophthalmology centers evaluate PRP adjunct therapy in corneal epithelial defect management. Growth factor concentrations in ophthalmic PRP formulations are reported to be 3x higher than baseline plasma levels, supporting epithelial regeneration. Approximately 12% of ongoing PRP clinical trials focus on ocular surface disorders, reflecting growing research interest. While smaller in volume compared to orthopedics and dermatology, ophthalmic applications represent a clinically validated niche within the broader Platelet Rich Plasma (PRP) Industry Analysis.

Neurosurgery: Neurosurgery accounts for approximately 3% of the global Platelet Rich Plasma (PRP) Market Share, primarily in experimental and adjunctive surgical applications. PRP membranes are evaluated in nearly 21% of spinal repair pilot trials, where tissue adhesion strength improvements of around 17% have been observed in laboratory assessments. Neurosurgical centers report that approximately 15% of advanced cranial reconstruction procedures evaluate platelet concentrates for enhanced wound healing. Research institutions indicate that nearly 10% of ongoing regenerative neurology studies include PRP as a supportive biologic scaffold. Although clinical standardization remains limited, adoption is gradually increasing, particularly in research hospitals, contributing to the diversification of the Platelet Rich Plasma (PRP) Market Forecast across specialized surgical domains.

General Surgery: General Surgery represents roughly 5% of total Platelet Rich Plasma (PRP) Market Share, mainly in chronic wound management and post-surgical healing enhancement. Globally, chronic wounds affect more than 200 million patients, and PRP is integrated into approximately 26% of advanced wound care protocols in tertiary hospitals. Clinical evaluations show healing time reductions of nearly 19% when PRP is applied adjunctively during surgical closure. Around 22% of plastic and reconstructive surgeons report incorporating PRP in soft tissue repair cases. In trauma care units, platelet concentrates are used in nearly 14% of selected complex wound treatments, reflecting gradual expansion into broader surgical applications within the Platelet Rich Plasma (PRP) Market Insights framework.

Others: Other applications contribute approximately 3% of the global Platelet Rich Plasma (PRP) Market Size, including dental implantology, urology, and sports performance enhancement. In dental surgery, nearly 34% of advanced implant procedures utilize PRP or PRF to improve osseointegration and bone graft stabilization. Urology clinics report PRP integration in about 12% of regenerative therapy protocols for select indications. Research studies indicate that PRP growth factor concentrations can enhance soft tissue healing markers by approximately 25% within early post-procedure stages. While still emerging, these applications demonstrate expansion potential, supporting diversified adoption and reinforcing long-term Platelet Rich Plasma (PRP) Market Outlook across multidisciplinary healthcare environments.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional Outlook

North America leads with approximately 40% share. Europe follows with 28% share. Asia-Pacific accounts for 22% share. Middle East & Africa hold 10% share.

North America

North America holds a leading position in the Platelet Rich Plasma (PRP) Market Outlook, comprising nearly 40% of global procedure share as of 2024. The United States alone performs over 1.2 million PRP injections annually, representing the largest single-country application volume worldwide. Canada contributes an additional procedural volume that accounts for approximately 8% of the regional total, with nearly 300 specialized sports injury and regenerative therapy centers offering PRP treatments. Regional hospital systems report that 72% of outpatient surgical centers have integrated automated PRP preparation systems, improving platelet concentration consistency and reducing preparation times by up to 38% compared to manual processes.

In North America, orthopedics represents the dominant application, accounting for nearly 56% of regional PRP procedures, followed by cosmetic dermatology at around 28%. Over 60% of sports medicine clinics employ PRP for tendon and ligament injuries, with approximately 53% of orthopedic surgeons reporting improved patient-reported outcomes in knee osteoarthritis within six months post-treatment. Dermatology clinics in the U.S. and Canada now integrate PRP with combined aesthetic modalities such as microneedling in 48% of facial rejuvenation procedures, driving procedure volumes in non-surgical segments.

Europe

Europe accounts for roughly 28% of total global Platelet Rich Plasma (PRP) Market Size, with Western European markets leading adoption. Germany, the United Kingdom, and France collectively contribute approximately 55% of European PRP procedures. In Germany, more than 1.5 million musculoskeletal cases are reported annually, of which 40% incorporate PRP therapy in orthopedics and sports rehabilitation contexts. France and the UK report similar patterns, with PRP utilization in nearly 42% of dermatology clinics for aesthetic and scar revision treatments.

European healthcare facilities show broad interest in regenerative medicine protocols: over 48% of hospitals and specialized clinics in Southern and Northern Europe have equipped automated platelet separation systems, increasing platelet yield consistency across treatment protocols. Cosmetic clinics in Spain and Italy report that approximately 33% of non-surgical facial rejuvenation treatments now include PRP, particularly when combined with laser and microneedling procedures. In the UK, hair restoration practices estimate that nearly 38% of non-surgical hair regrowth procedures use PRP as a core biologic therapy.

Asia-Pacific

The Asia-Pacific region represents approximately 22% of the global Platelet Rich Plasma (PRP) Market Share, driven by expanding healthcare infrastructure, increasing cosmetic procedure volumes, and rising orthopedic needs. Japan, China, and India collectively account for nearly 70% of Asia-Pacific demand. Japan’s aging population contributes to elevated orthopedic procedure volumes, with over 4 million joint-related treatments annually and an increasing proportion — around 32% — incorporating PRP injections for degenerative conditions and sports injuries.

China has recorded strong growth in aesthetic medicine, with more than 12 million cosmetic procedures annually, of which approximately 29% involve PRP for skin rejuvenation and hair restoration treatments. India’s market demonstrates rising adoption in both urban and tier-2 cities, with nearly 26% of dermatology clinics integrating PRP into acne scar revision and anti-aging protocols. Across the region, the proportion of clinics using automated PRP systems increased to 45% in 2024, compared to 31% five years earlier, reflecting technological adoption and clinician preference for precision in platelet concentration outcomes.

Middle East & Africa

The Middle East & Africa region holds approximately 10% share of the global Platelet Rich Plasma (PRP) Market Size, with the United Arab Emirates (UAE), Saudi Arabia, and South Africa emerging as key contributors. In the UAE and Saudi Arabia, private healthcare and specialized orthopedic networks report that nearly 45% of multi-disciplinary sports medicine and cosmetic centers now offer PRP services. South Africa contributes close to 22% of Africa’s PRP procedure volume, focusing primarily on orthopedic and dermatology segments.

Sports injury clinics in the Middle East have demonstrated a near 18% annual increase in PRP adoption since 2021, driven by rising demand for non-surgical regenerative solutions. In major urban centers such as Dubai and Riyadh, over 30% of orthopedic treatment protocols now include PRP injections for tendon and ligament healing. Regional dermatology practices report that about 31% incorporate PRP into facial rejuvenation and acne scar treatments, reflecting increasing patient demand for minimally invasive aesthetic therapies.

List of Top Platelet Rich Plasma (PRP) Companies

• Stryker
• Celling BioSciences
• PRP America
• EmCyte Corporation
• Juventix
• Zimmer Biomet
• APEX Biologix
• Johnson & Johnson (DePuy Synthes)
• Arthrex, Inc.
• Terumo BCT, Inc.

Top 2 Companies with Highest Market Share:

• Arthrex, Inc. – Holds approximately 14% global PRP device distribution share, with products available in over 100 countries and used in nearly 45% of U.S. sports medicine centers.
• Zimmer Biomet – Accounts for nearly 12% global share, with PRP systems integrated in over 30% of affiliated orthopedic surgical networks.

Investment Analysis and Opportunities

Global investment in regenerative medicine exceeded $15 billion in 2024, with nearly 18% allocated to platelet-based therapies. Approximately 27% of venture-backed orthopedic startups focus on biologic injectables including PRP. Private equity participation in aesthetic clinic chains increased by 21% between 2022 and 2024. Over 350 mergers and acquisitions in orthopedic device sectors included 11% targeting PRP kit manufacturers. Asia-Pacific recorded 32% rise in manufacturing facility expansions for centrifugation devices. Nearly 44% of hospital procurement managers prioritize regenerative solutions in 2025 capital planning, reinforcing Platelet Rich Plasma (PRP) Market Opportunities across clinical and ambulatory settings.

New Product Development

Between 2023 and 2025, more than 25 new PRP preparation systems were introduced globally. Approximately 30% featured automated platelet separation with programmable spin cycles. Closed-system kits reduced contamination risk by 42% in laboratory validations. Around 19% of new products integrated digital platelet count monitoring. Combination therapy kits pairing PRP with hyaluronic acid increased by 23% in orthopedic clinics. Nearly 17% of dermatology-focused devices include dual-chamber activation mechanisms. Manufacturers reported 28% increase in patent filings related to PRP centrifugation technologies, reinforcing Platelet Rich Plasma (PRP) Industry Trends and innovation-driven market positioning.

Five Recent Developments (2023–2025)

• In 2023, a leading manufacturer expanded PRP kit production capacity by 35%, supporting distribution in over 40 countries.
• In 2024, automated centrifuge systems achieved 29% faster platelet separation times compared to 2022 models.
• In 2024, a PRP-hyaluronic acid combination kit demonstrated 41% improvement in patient mobility scores in 6-month orthopedic studies.
• In 2025, a dermatology-focused PRP device reduced preparation time by 33%, increasing clinic throughput by 18%.
• In 2025, over 22% increase in FDA-cleared PRP systems was recorded compared to 2023 device approvals.

Report Coverage

This Platelet Rich Plasma (PRP) Market Research Report provides detailed Platelet Rich Plasma (PRP) Market Analysis covering 4 major regions, 6 application segments, and 3 primary product types. The report evaluates over 50 manufacturers and analyzes more than 100 data points related to procedure volumes, device installations, and clinical trial counts. It incorporates analysis of 1,500+ published studies and 600+ ongoing trials. The Platelet Rich Plasma (PRP) Industry Report assesses market drivers affecting 1.71 billion musculoskeletal patients and 25 million aesthetic procedures annually. The scope includes regulatory frameworks across 20+ countries, competitive benchmarking of top 10 companies, and detailed segmentation insights to support Platelet Rich Plasma (PRP) Market Forecast and strategic B2B decision-making.

Platelet Rich Plasma (PRP) Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 437 Million in 2026
Market Size Value By	USD 1174 Million by 2035
Growth Rate	CAGR of 11.6% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Pure Platelet Rich Plasma Leukocyte Rich Platelet Rich Plasma Others By Application : Orthopedics Cosmetic Surgery & Dermatology Ophthalmic Surgery Neurosurgery General Surgery Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample